Merck will pay Acceleron $180 per share in cash.
Acceleron develops drugs to treat cardiovascular and other blood-related disorders.The deal allows Merck to take over Acceleron’s lead drug candidate sotatercept. Merck will also gain access to Reblozyl, a drug Acceleron developed to treat anemia in certain rare blood disorders.
“Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease,” Rob Davis, Merck’s CEO and president, said in a news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
